The BLyS family: toward a molecular understanding of B cell homeostasis - PubMed (original) (raw)
Review
The BLyS family: toward a molecular understanding of B cell homeostasis
John F Treml et al. Cell Biochem Biophys. 2009.
Abstract
The B Lymphocyte Stimulator (BLyS) family of ligands and receptors regulates humoral immunity by controlling B lymphocyte survival and differentiation. Herein, we review the ligands and receptors of this family, their biological functions, and the biochemical processes through which they operate. Pre-immune B lymphocytes rely on BLyS signaling for their survival, whereas antigen experienced B lymphocytes generally interact more avidly with a homologous cytokine, A Proliferation Inducing Ligand (APRIL). The molecular basis for signaling via the three BLyS family receptors reveals complex interplay with other B lymphocyte signaling systems, affording the integration of selective and homeostatic processes. As our understanding of this system advances, molecular targets for manipulating humoral immunity in both health and disease should be revealed.
Figures
Fig. 1
Receptor Expression and Cytokine Dependence. B cells in pre-immune subsets express both BR3 and TACI, but only BLyS is required for their normal development. Antigenic stimuli result in changes in receptor expression. T cell dependent stimuli favor BR3 expression and lead to germinal center reactions, while T cell independent stimuli favor TACI expression on the resulting short-lived plasma cells. Although all recently activated B cells express one or more BLyS receptors, the exact roles played by BLyS and/or APRIL in their survival or differentiation has not been fully interrogated. Long-lived bone marrow plasma cells express BCMA, and require APRIL for normal survival. Memory cells express TACI, but are largely independent of either BLyS or APRIL
Similar articles
- Manipulating B cell homeostasis: a key component in the advancement of targeted strategies.
Treml LS, Quinn WJ 3rd, Treml JF, Scholz JL, Cancro MP. Treml LS, et al. Arch Immunol Ther Exp (Warsz). 2008 May-Jun;56(3):153-64. doi: 10.1007/s00005-008-0017-2. Epub 2008 May 30. Arch Immunol Ther Exp (Warsz). 2008. PMID: 18512030 Free PMC article. Review. - APRIL/BLyS Blockade Reduces Donor-specific Antibodies in Allosensitized Mice.
Wilson NA, Bath NM, Verhoven BM, Ding X, Boldt BA, Sukhwal A, Zhong W, Panzer SE, Redfield RR 3rd. Wilson NA, et al. Transplantation. 2019 Jul;103(7):1372-1384. doi: 10.1097/TP.0000000000002686. Transplantation. 2019. PMID: 30830041 Free PMC article. - New roles for the BLyS/BAFF family in antigen-experienced B cell niches.
Goenka R, Scholz JL, Sindhava VJ, Cancro MP. Goenka R, et al. Cytokine Growth Factor Rev. 2014 Apr;25(2):107-13. doi: 10.1016/j.cytogfr.2014.01.001. Epub 2014 Jan 10. Cytokine Growth Factor Rev. 2014. PMID: 24507939 Free PMC article. Review. - B cells and the BAFF/APRIL axis: fast-forward on autoimmunity and signaling.
Mackay F, Silveira PA, Brink R. Mackay F, et al. Curr Opin Immunol. 2007 Jun;19(3):327-36. doi: 10.1016/j.coi.2007.04.008. Epub 2007 Apr 12. Curr Opin Immunol. 2007. PMID: 17433868 Review. - The BLyS/BAFF family of ligands and receptors: key targets in the therapy and understanding of autoimmunity.
Cancro MP. Cancro MP. Ann Rheum Dis. 2006 Nov;65 Suppl 3(Suppl 3):iii34-6. doi: 10.1136/ard.2006.058412. Ann Rheum Dis. 2006. PMID: 17038469 Free PMC article. Review.
Cited by
- Targeting chronic lymphocytic leukemia with B-cell activating factor receptor CAR T cells.
Qie Y, Gadd ME, Shao Q, To T, Liu A, Li S, Rivera-Valentin R, Yassine F, Murthy HS, Dronca R, Kharfan-Dabaja MA, Qin H, Luo Y. Qie Y, et al. MedComm (2020). 2024 Sep 2;5(9):e716. doi: 10.1002/mco2.716. eCollection 2024 Sep. MedComm (2020). 2024. PMID: 39224539 Free PMC article. - Current status of BAFF targeting immunotherapy in B-cell neoplasm.
Tagami N, Yuda J, Goto Y. Tagami N, et al. Int J Clin Oncol. 2024 Nov;29(11):1676-1683. doi: 10.1007/s10147-024-02611-2. Epub 2024 Sep 2. Int J Clin Oncol. 2024. PMID: 39222149 Free PMC article. Review. - A PRoliferation-Inducing Ligand (APRIL) in the Pathogenesis of Immunoglobulin A Nephropathy: A Review of the Evidence.
Mathur M, Chan TM, Oh KH, Kooienga L, Zhuo M, Pinto CS, Chacko B. Mathur M, et al. J Clin Med. 2023 Nov 4;12(21):6927. doi: 10.3390/jcm12216927. J Clin Med. 2023. PMID: 37959392 Free PMC article. Review. - B Cell Tolerance and Targeted Therapies in SLE.
Parodis I, Long X, Karlsson MCI, Huang X. Parodis I, et al. J Clin Med. 2023 Sep 28;12(19):6268. doi: 10.3390/jcm12196268. J Clin Med. 2023. PMID: 37834911 Free PMC article. Review. - Considerations for Novel COVID-19 Mucosal Vaccine Development.
Alturaiki W. Alturaiki W. Vaccines (Basel). 2022 Jul 23;10(8):1173. doi: 10.3390/vaccines10081173. Vaccines (Basel). 2022. PMID: 35893822 Free PMC article. Review.
References
- Schiemann B, Gommerman JL, Vora K, Cachero TG, Shulga-Morskaya S, Dobles M, et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science. 2001;293:2111–2114. - PubMed
- Schneider P, Takatsuka H, Wilson A, Mackay F, Tardivel A, Lens S, et al. Maturation of marginal zone and follicular B cells requires B cell activating factor of the tumor necrosis factor family and is independent of B cell maturation antigen. Journal of Experimental Medicine. 2001;194:1691–1697. - PMC - PubMed
- Casola S, Otipoby KL, Alimzhanov M, Humme S, Uyttersprot N, Kutok JL, et al. B cell receptor signal strength determines B cell fate. Nature Immunology. 2004;5:317–327. - PubMed
- Do RK, Chen-Kiang S. Mechanism of BLyS action in B cell immunity. Cytokine and Growth Factor Reviews. 2002;13:19–25. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 AI054488/AI/NIAID NIH HHS/United States
- R01 AI054488-05/AI/NIAID NIH HHS/United States
- R01 AI073939/AI/NIAID NIH HHS/United States
- R01 AI073939-01/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous